Sanofi to Acquire Vigil Neuroscience in $470 Million Deal to Boost Neurological Pipeline
May 22 (Reuters) - Sanofi will acquire Vigil Neuroscience, a clinical-stage biotech company in a $470 million deal, the companies said on Thursday, as the French drugmaker seeks to boost its neurologi